HCAMEDIUM SIGNALFINANCIAL10-K

HCA substantially increased share buybacks while expanding operations with new ASCs and endoscopy centers, though cash reserves declined significantly.

The company's aggressive capital allocation strategy reflects management confidence in generating strong cash flows, evidenced by solid operating cash flow growth and higher net income. However, the substantial reduction in cash reserves combined with dramatically higher buybacks suggests a more leveraged approach to capital management that investors should monitor for sustainability.

Comparing 2026-02-10 vs 2025-02-14View on EDGAR →
FINANCIAL ANALYSIS

HCA demonstrated strong operational performance with operating cash flow growing 20% to $12.6B and net income rising 18% to $6.8B. The company substantially increased share buybacks to $10.1B, representing a much more aggressive return of capital to shareholders. However, this expansion in buybacks came alongside a notable decline in cash reserves to $1.0B, indicating management's willingness to operate with lower liquidity buffers while pursuing shareholder-friendly capital allocation.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+66.6%
$6.0B$10.1B

Share repurchases increased 66.6% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
-46.2%
$1.9B$1.0B

Cash declined 46.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
+20.2%
$10.5B$12.6B

Operating cash flow grew 20.2% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+17.8%
$5.8B$6.8B

Net income grew 17.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-10
PRIOR — 2025-02-14
ADDED
As of June 30, 2025, the aggregate market value of the common stock held by nonaffiliates was approximately $ 63.269 billion.
At December 31, 2025, we operated 190 hospitals, comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals.
In addition, we operated 121 freestanding ambulatory surgery centers ( ASCs ) and 31 freestanding endoscopy centers.
3 To achieve these objectives, we align our efforts around the following growth agenda: grow our presence in existing markets; achieve industry-leading performance in clinical, operational and satisfaction measures; recruit and retain physicians and other health care professionals to meet the need for high-quality health services; continue to utilize economies of scale to grow the Company; pursue a disciplined development strategy; and advance our digital and artificial intelligence ( AI ) capabilities.
At December 31, 2025, we owned and operated 179 general, acute care hospitals with 50,436 licensed beds.
+7 more — sign up free →
REMOVED
As of June 30, 2024, the aggregate market value of the common stock held by nonaffiliates was approximately $ 60.369 billion.
At December 31, 2024, we operated 190 hospitals, comprised of 180 general, acute care hospitals; six behavioral hospitals; and four rehabilitation hospitals.
In addition, we operated 124 freestanding ambulatory surgery centers ("ASCs") and 26 freestanding endoscopy centers.
We make available free of charge, through our website, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Exchange Act, as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC.
Our Code of Conduct is available free of charge upon request to our Investor Relations Department, HCA Healthcare, Inc., One Park Plaza, Nashville, Tennessee 37203, and is also available on the Ethics and Compliance and Governance Documents portion of our website at www.hcahealthcare.com.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →